LabCorp Enhances VistaSeq Hereditary Cancer Test Portfolio with Addition of New Panels and New Genes That Can Be Assessed

Expanded Test Offering Provides Targeted Insight into Risk for Hereditary Cancer Syndromes BURLINGTON, N.C. --(BUSINESS WIRE)--May 3, 2017-- LabCorp® (NYSE: LH) today announced a significant enhancement to its proprietary VistaSeq SM Hereditary Cancer portfolio, with ten new test panels focusing on

LabCorp’s Acquisition of Pathology Associates Medical Laboratories Clears Antitrust Review

BURLINGTON, N.C. --(BUSINESS WIRE)--May 1, 2017-- LabCorp® (NYSE: LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to LabCorp’s acquisition of Pathology Associates Medical Laboratories, LLC (PAML) has expired.

LabCorp Completes Acquisition of Assets of Mount Sinai Health System Clinical Outreach Laboratories

Transaction will benefit physicians and patients in metropolitan New York City BURLINGTON, N.C. --(BUSINESS WIRE)--May 1, 2017-- LabCorp ® (NYSE: LH), a leading global life sciences company, has completed the previously announced acquisition of assets of the Mount Sinai Health System Clinical

LabCorp to Exclusively Offer the M3 Checklist, a Multi-Condition Mental Health Screening Tool

The M3 Checklist Helps to Identify and Monitor Common Mental Health Conditions in the Primary Care Setting BURLINGTON, N.C. & ROCKVILLE, Md. --(BUSINESS WIRE)--Apr. 28, 2017-- LabCorp ® (NYSE:LH) and M-3 Information, LLC today announced the nationwide availability through LabCorp of the

Laboratory Corporation of America® Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance

Q1 Net revenue of $2.4 billion , up 5% over last year Q1 Diluted EPS of $1.84 , up 16% over last year; Q1 Adjusted EPS of $2.22 , up 8% over last year Q1 Free Cash Flow of $162 million , up 188% over last year 2017 Adjusted EPS guidance updated to $9.20 to $9.60 , up 4% to 9% over 2016 BURLINGTON,

Covance to Expand Large-Molecule Development Capabilities in the UK

Covance Drug Development continues to invest in precision medicine with expansion into laboratory space at York facility BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 21, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a leading global life sciences company, announced today

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 3, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Commends Reps. Dr. Bucshon, DeGette for Releasing Bipartisan Discussion Draft of the Diagnostic Accuracy and Innovation Act (DAIA)

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 30, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today issued the following statement regarding a discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA) recently released by

LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 29, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today announced that Gary Huff is being promoted to CEO of LabCorp Diagnostics, one of the company’s two primary business segments, effective

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 13, 2017-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of March 12, 2017 to September 11, 2017 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to